WO1993006218A2 - Chimeras of parainfluenza virus type 3 proteins f and hn as vaccines - Google Patents
Chimeras of parainfluenza virus type 3 proteins f and hn as vaccines Download PDFInfo
- Publication number
- WO1993006218A2 WO1993006218A2 PCT/EP1992/002174 EP9202174W WO9306218A2 WO 1993006218 A2 WO1993006218 A2 WO 1993006218A2 EP 9202174 W EP9202174 W EP 9202174W WO 9306218 A2 WO9306218 A2 WO 9306218A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fusion
- plasmid
- fusion protein
- immunogenic derivative
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 73
- 102000004169 proteins and genes Human genes 0.000 title claims description 67
- 229960005486 vaccine Drugs 0.000 title claims description 17
- 241000712003 Human respirovirus 3 Species 0.000 title description 2
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims abstract description 34
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 28
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 28
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000002163 immunogen Effects 0.000 claims abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 235000018102 proteins Nutrition 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 23
- 239000012528 membrane Substances 0.000 claims description 18
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 108020004511 Recombinant DNA Proteins 0.000 claims description 8
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 23
- 239000012634 fragment Substances 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 12
- 241000700605 Viruses Species 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 241000700618 Vaccinia virus Species 0.000 description 8
- 206010046865 Vaccinia virus infection Diseases 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 208000007089 vaccinia Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 6
- 102000005396 glutamine synthetase Human genes 0.000 description 6
- 108020002326 glutamine synthetase Proteins 0.000 description 6
- 102000051251 human MPO Human genes 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 4
- 241001045988 Neogene Species 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100024806 Small integral membrane protein 6 Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to recombinant PIV 3 proteins, more particularly to the F and HN proteins, fusion proteins derived therefrom, and their expression in eukaryotic cells.
- the invention further relates to methods of constructing and expressing the said fusion proteins, intermediates for use therein and recombinant proteins which may be obtained from the intermediates.
- Recombinant proteins of the invention have potential utility in the development of vaccines for the prevention of PIV 3 infection.
- Parainfluenza viruses are important pathogens of the respiratory tract in infants and young children. Some infections are not restricted to the upper respiratory tract but also invade the lower part of the respiratory system, particularly in children under 5 years of age. For a review see Parainfluenza Viruses (chapter 35); Channock, R.M. and Mclntosh, K. (1990) Virology. Second Edition, edited by B.N. Fields and D.N. Knipe. Raven Press, Inc. N.Y.; pp 963-988.
- PrV3 infections are not only associated with the croup syndrome (as in the case of PIVl and PIV2) but more often cause bronchitis, bronchiolitis and pneumonia. PrV3 is responsible for most of the fatal infections observed with paramyxoviruses. In particular, severely immuno-compromised children are at risk of developing fatal giant cell pneumonia when infected with PTV3. (Jarvis, W.R.; Middleton, P.J. and Gelfand, E.W. (1979). J. Pediatr. 24, 423-425)
- the fusion protein F of PrV3 contains 539 amino acid residues; amino acids 1 to 18 correspond to the signal peptide and residues 494 to 516 to the membrane anchor domain.
- the molecule presents potential sites for glycosylation.
- the F protein is synthesized as a 70 kDa precursor (Ffj) which undergoes proteolytic maturation to yield the Fi (56kDa) and F2 (14 kDa) subunits linked via disulfide bridges.
- the protein F when injected into animals, leads to the production of neutralizing antibodies.
- the F protein is involved in cell fusion during viral infection and carries an hemolys ⁇ n activity. Used alone for immunization, the F protein generates an immune response which is insufficient to confer protection against a challenge with the virus. Complete protection is only acquired by concomitant immunization with the protein HN, another glycoprotein ofPrV3.
- the protein HN carries hemaglutinin and neuraminidase activities. It is composed of 572 amino acids; its membrane anchor domain occurs in the N-terminal end of the molecule, between amino acid residues 32 and 53. Four potential sites for glycosylation have been identified. Injection of protein HN into animals generates an immune response and neutralizing antibodies. These antibodies however do not protect completely against a challenge with the virus. Full protection is obtained only by concomitant immunization with the F protein of PTV3.
- recombinant DNA encoding a fusion protein or an immunogenic derivative thereof comprising a portion of the F protein of PIV3 fused to a portion of the HN protein of PTV3.
- immunogenic derivative encompasses any molecule which is a fusion protein which is immunologically reactive with antibodies raised to the fusion protein of the present invention or parts thereof or which elicits antibodies recognizing the fusion protein, the HN protein, the F protein or PIV3 virus.
- immunogenic derivatives which are slightly longer or shorter than the fusion protein of the present invention may be used.
- Such derivatives may , for example, be prepared by substitution, addition, or rearrangement of amino acids or by chemical modifications thereof including those for enabling coupling of the fusion protein to other carrier proteins such as tetanus toxoid or Hepatitis B surface antigen. All such substitutions and modifications are generally well known to those skilled in the art of peptide chemistry.
- Immunogenic fragments of the fusion protein which may be useful in the preparation of vaccines may be prepared by expression of the appropriate gene fragments or by peptide synthesis, for example using the Merrifield synthesis (The Peptides, Vol 2., Academic Press, New York, p3).
- the recombinant DNA of the invention may form part of a vector, for example a plasmid, especially an expression plasmid from which the fusion protein may be expressed.
- a vector for example a plasmid, especially an expression plasmid from which the fusion protein may be expressed.
- Such vectors also form part of the invention, as do host cells into which the vectors have been introduced.
- the invention further provides a fusion (or "hybrid') protein or an immunogenic derivative thereof comprising a portion of the F protein of PF73 fused to a portion of the HN protein of PrV3.
- a fusion or "hybrid') protein or an immunogenic derivative thereof comprising a portion of the F protein of PF73 fused to a portion of the HN protein of PrV3.
- the fusion is between an amino acid in the C-terminal part of a portion of the F protein and an amino acid at the N-terminus of a portion of the HN protein.
- both the F protein and the HN protein components of the fusion protein of the invention lack a membrane anchor domain.
- a fusion protein comprising amino acid residues 1 to 484 of the F protein fused to residues 88 to 572 of the HN protein (herein designated Fs + a- x HNa").
- cDNA containing the complete coding sequences of the F and HN proteins may be manipulated using standard techniques [see for example Maniatis T. et al Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y. (1982)] as further described hereinbelow. Tn the course of carrying out such techniques recombinant DNA encoding fragments of the F and HN proteins may be obtained which further forms part of the present invention.
- DNA segments encoding the truncated protein Fs + a' (F protein lacking the membrane anchor domain) and the truncated protein HNa" (HN protein lacking the 5' membrane anchor domain) are important intermediates.
- a further construct which may be obtained is DNA encoding the HNa " protein fused to a signal sequence from another gene, for example human myeloperoxidase (MPO).
- MPO myeloperoxidase
- a particular embodiment is ⁇ HN corresponding to a hybrid containing the 22 amino acid signal peptide of MPO fused to the last 519 amino acid residues of the HN protein (aa 53 to 572).
- Vectors comprising such DNA, hosts transformed thereby and the truncated or hybrid proteins themselves, expressed as described hereinbelow all form part of the invention.
- plasmids may be constructed which are suitable either for transfer into vaccinia virus or transfection into Chinese Hamster Ovary (CHO) cells or Vero cells. Suitable expression vectors are described hereinbelow.
- vaccinia transfer plasmid such as pTJLB 5213 which is a derivative of pSCll (Chakrabati ⁇ £ a . Molecular and Cellular Biology 5_, 3403 - 3409, 1985) may be used.
- the protein may be expressed under the control of the vaccinia P7.5 promoter.
- GS glutamine synthetase
- pEE14 glutamine synthetase vector
- pEE14 glutamine synthetase vector
- a vector which allows the expression of the coding module as a polycistronic transcript with the neo selection gene may suitably be used.
- the coding module is under the control of the Rous Sarcoma Long Terminal Repeat (LTR) promoter.
- LTR Rous Sarcoma Long Terminal Repeat
- the plasmid for expression in CHO cells carries a DHFR expression cassette suitable for gene amplification using methotrexate.
- Figure IA shows a schematic representation of the Fs + a" cDNA module which was used to construct a plasmid pNTV3305;
- Figure IB shows a representation of plasmid pNIV3324 obtained by introducing the Fs + a" module into pULB 5213;
- Figure 2A shows a representation of plasmid pNIV3308 carrying the sequence of HNa"
- Figure 2B is a representation of plasmid pNTV3325 obtained by introducing the HNa" module into pULB5213;
- Figure 3 is a representation of plasmid pNTV3327 obtained by introducing the SSMPO module into pULB5213;
- Figure 4A is a representation of plasmid pNTV3310 obtained by introducing the FxHN DNA sequence into pUC9;
- Figure 4B is a representation of plasmid pN3V3326 obtained by introducing the FxHN DNA sequence into pULB5212;
- Figure 5 is a representation of the Fs + a" coding module as subcloned in a pTDN vector to give plasmid pNIV3306 together with a representation of pRIT13572 containing the Fs + a" coding module subcloned into pEE14;
- Figure 6 is a representation of the Fs + a" x HNa" coding module recovered from pNrV3310 together with pRIT13571 containing the Fs+a" x HNa” sequence subcloned into pEE14;
- Figure 7 is a representation of the complete HN protein coding sequence from plasmid pIBI-HN together with pNTV3328 containing the HN coding sequence subcloned into pTNDPC2;
- Figure 8 is a representation of the HNa' coding module recovered from pNTV3308 together with pNTV3331 containing the HNa" coding sequence subcloned into pTNDPC2;
- Figure 9A is a representation of the pNTV3319 containing the HNa" coding sequence subcloned into a pTDN vector
- Figure 9B shows the construction of plasmid pNTV3321 containing the SSMPO ⁇ HN coding sequence from pNTV3319 and pNTV2706;
- Figure 9C shows the SS ⁇ PO ⁇ ELN sequence from pNTV3321 introduced into pTNDPC2 to form pNTV3330.
- a vaccine composition comprising a protein according to the invention in combination with a pharmaceutically acceptable carrier, a protein according to the invention for use in vaccinating a host and the use of a protein according to the invention in the preparation of a vaccine.
- the Pr 3 vaccine of the present invention is combined with other immunogens to afford a polyvalent vaccine.
- the invention further provides a vaccine composition
- a vaccine composition comprising a protein according to the invention and an antigen against respiratory syncytial virus (RSV) together with a suitable carrier or adjuvant.
- RSV respiratory syncytial virus
- Antigens which stimulate production of antibodies against RSV in humans and animals are known in the art and examples are the major glycoprotein (G), fusion protein (F), phosphoprotein (P), nucleoprotein (N), and matrix (22K) protein of RSV A2 strain (a general review is given by Stott, E.J. and Taylor, G. (1985) in Archives of Virology,84, 1-52).
- Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller ei l, University Park Press, Baltimore, Maryland, U.S.A., 1978. Encapsulation within liposomes is described, for example by Fullerton, U.S. Patent 4,235,877.
- an aqueous solution of the protein(s) can be used directly.
- the protein, with or without prior lyophilisation can be mixed, absorbed or adsorbed with any of the various known adjuvants.
- adjuvants include, but are not limited to , alumimum hydroxide, muramyl dipeptide and saponins such as Quil A.
- Particularly preferred adjuvants are MPL (monophosphoryl lipid A) and 3D-MPL (3 deacylated monophosphoryl lipid A) [US patent 4,912,094].
- a further preferred adjuvant is known as QS21 which can be obtained by the method disclosed in US patent 5,057,540.
- 3D-MPL Use of 3D-MPL is described by Ribi ⁇ £ s in Microbiology (1986) Levie ⁇ £ aL(eds) Amer. Soc. Microbiol.Wash. D.C., 9-13. Use of Quil A is disclosed by Dalsgaard ⁇ £ al,(1977), Acia Ve cand. IS, 349.
- the proteins can be encapsulated within microparticles such as liposomes or associated with oil-in-water emulsions. Encapsulation within liposomes is described by Fullerton in US patent 4,235,877.
- the proteins can be conjugated to an immunostimulating macromolecule, such as killed Bordetella or a tetanus toxoid. Conjugation of proteins to macromolecules is disclosed, for example by Likhite in patent 4,372,945 and Armor el a in US patent 4,474,757.
- each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 1-200 ⁇ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects.
- Plasmid pIBIcod was digested by Nsil and BamHI to recover a 4016 bp DNA fragment corresponding to the vector and amino acid residues 1 to 377 of the F protein.
- a 362 bp Nsil-BamHI DNA piece was generated by the polymerase chain reaction using plasmid pIBIcod as template; it corresponds to amino acid residues 378 to 493 of the F protein and includes a stop codon.
- This fragment was ligated to the 4016 bp DNA piece obtained before to reconstruct a plasmid, pNTV3305, carrying the F protein lacking the anchor domain (Fig. IA).
- the Fs + a" module (1492 bp) was then recovered from pNTV3305 by digestion with Hindm-BamHI and introduced blunt-ended, in the correct orientation for expression, into the Smal site of the vaccinia transfer plasmid pULB5213, which is a derivative of the standard vaccinia vector pSCll (Chakrabati e al. Molecular and Cellular Biology £, 3403-3409, 1985).
- the resulting plasmid, pNTV3324 is illustrated in Fig. IB.
- HNa a cDNA clone containing the complete coding sequence of protein HN as well as its 3' non coding sequence (received from Dr.K. Kimock, University of Ottawa, Canada), we reconstructed two different cDNA modules coding for the HN protein lacking the 5' membrane anchor domain.
- the first one, HNa consists of a strict deletion of amino acid residues 32 to 51 and the second one, SSMPQ HN, consists of a fusion between a synthetic signal sequence derived from the human myeloperoxidase cDNA (Moguilevsky et al. Eur. J. Bicohemistry, 19J7_: 605-614, 1991) and amino acid residues 54 to 572 of the HN protein.
- the module coding for HNa was constructed as follows: plasmid pIBI-HN was digested with Asn718 and EcoRI to recover a 3935 bp DNA fragment corresponding to the vector and to amino acid residues 236 to 572 of the HN protein. In addition, two DNA fragments were generated by the polymerase chain reaction procedure using plasmid pIBI-HN as template; the first one is 117 bp EcoRI-HindlH piece spanning the initiation ATG (Metl), the sequence coding for amino acids 2 to 31 and the codon for amino acid residue 52 of the HN protein. The second fragment is a 556 bp HindHI-Asp718 DNA piece encoding amino acid residues 53 to 235 of the HN protein.
- pNTV3308 carries the sequence of the HN protein lacking exclusively the anchor domain (sequence for amino acids 32 to 51).
- the HNa module (1688 bp) was then recovered from pNTV3308 by digestion with Xbal and introduced blunt-ended into the Smal site of the vaccinia transfer vector pULB5213 (see supra).
- the resulting plasmid, pNIV3325 is illustrated in Fig.2B.
- the module coding for SSMPO A HN was constructed as follows: starting from plasmid pNTV3325 Fig 9B), which carries an hybrid sequence corresponding to the signal peptide (22 amino acids) of human myeloperoxidase fused to the last 519 amino acid residues of the HN protein (aa53 to 572), we excised a 1649 bp Bspl286I-BamHI DNA fragment which, after blunting, was ligated into the Smal site of the vaccinia transfer plasmid pULB5213.
- pNIV3327 The resulting plasmid, pNIV3327, is illustrated in Fig. 3.
- the DNA coding for the HNa" protein is fused downstream to the DNA encoding the Fs + a" protein.
- Plasmid pIBIcod (see supra) was digested with BamHI and Bj£LTI to recover a 4284 bp fragment corresponding to the vector and to amino add residues 1 to 466 of the F protein.
- plasmid pT-BI-HN (see supra) was digested with BamHI and Asel to recover a 1467 bp DNA piece corresponding to amino add residues 88 to 572 of the HN protein.
- synthetic oligonucleotides (56/54 mers) were produced in order to provide the junction between the two fragments obtained above. These oligonucleotides are flanked by a BglTJ site on the 5' end and an Asel site on the 3' end, and code for amino add residues 467 to 484 of the F protein.
- the three DNA fragments were ligated to generate the plasmid pNTV3309.
- pUC9 Pierada
- pNTV3310 Fig.4A
- the hybrid FxHN DNA sequence 2949bp was recovered from pNLV3310 by digested with BamHI and introduced by ligation into the BgHI site of the vacdnia transfer plasmid pULB5212 (pULB5212 is identical to pULB5213 except for the orientation of the multisite linker sequence; see supra) to generate the final plasmid pNTV3326 (Fig.4B).
- This plasmid thus contains, under the control of the vacdnia P7 5 promoter, an hybrid DNA sequence coding for 969 amino adds (residues 1 to 484 of the F protein fused to residues 88 to 572 of the HN protein.
- the module coding for Fs + a recovered from pNTV3305, was subcloned into the pTDN vector (Connors et al. DNA 2:651-660, 1988) in order to provide appropriate flanking restriction sites for future constructions.
- the resulting intermediate plasmid, pNTV3306, was then digested with Hmdi ⁇ and SnaBI to recover the 1492 bp coding module.
- the DNA piece was ligated into the HindHI and Smal sites of the glutamine synthetase (GS) vector, pEE14 (Cockett ⁇ tal, Bio/Technology 8_:662-667, 1990).
- the resulting final plasmid, pRIT13572 contains the Fs + a ⁇ protein under the control of the major immediate early promoter of the human cytomegalovirus (hCMV-MIE).
- the recombinant plasmid is illustrated in Figure 5. 2.
- the starting material pNTV3310 was digested with BamHI to recover the module encoding the Fs + a"xNHa hybrid protein. This fragment was inserted, blunt-ended and in the correct orientation for expression, by ligation into the Smal site of the pEE14 vector (see supra).
- the resulting plasmid, pRIT13571 contains under the control of the hCMC promoter, the sequence coding for the fusion between Fs + a" (aa residues 1 to 484) and HNa" (aa residues 88 to 572); it is illustrated in Fig. 6.
- HN corresponds to the full coding sequence of the attachment protein, including the 5' membrane anchor domain.
- the second construction is the HNa" derivative, i.e. the attachment protein lacking exdusively the anchor sequence (amino add residues 31 to 52) and the third construction, ⁇ HN, is a fusion between the signal sequence of human myeloperoxidase and a truncated form of the attachment protein.
- the starting material, pIBI-HN was digested with BamHI to recover a 1736 bp DNA piece encoding the complete HN protein.
- the fragment was ligated, blunt-ended, to the blunted HindHI and Hpal sites of the eukaryotic expression vector pTNDPC2 (M.Reff, SmithKline Beecham, Philadelphia, USA).
- This vector is a derivative of pTDN (Connors et al. 1988, see supra) which allows the expression of a foreign DNA as a polydstronic transcript with the neo selection gene.
- the resulting plasmid, pNIV3328 thus carried the HN coding module upstream to the neo gene under the control of the Rous Sarcoma Long Terminal Repeat (LTR) promoter.
- the plasmid carried a DHFR expression cassette suitable for amplication using methotrexate.
- the plasmid is illustrated in Figure 7.
- the starting material, pNLV3308 was digested with Xbal to recover a 1684 bp fragment encoding the HNa" protein.
- the DNA piece was ligated, blunt-ended, to the blunted HindJU and Hpal sites of the eukaryotic polydstronic expression vector pTNDPC2 (see supra).
- the resulting plasmid, pNTV3331 carries the HNa" coding module upstream to the neo gene under the control of the RSVLTR promoter ( Figure 8).
- the final plasmid for expression of SSMPQ. ⁇ HN in CHO cells was obtained in three steps. The first one consists in introducing the Xbal-Xbal 1684 bp coding cassette derived from pNTV3308 (see above, b) into the pTDN vector (Connors et al. 1988, see supra) to obtain the intermediate vector pNTV3310 (Fig.9A). From there, the actual construction of SSMPQ A HN was started. pNTV3319 was digested in Sail and EcoRI to recover a 7278 bp fragment corresponding to the nearly complete vector and to the HN amino adds 53 to 572.
- plasmid pNTV2706 (Moguilevsky et al. Eur.J. Biochemistry jL9_Z:605-614, 1991) which encodes human myeloperoxidase, was digested with Sail and Bgi ⁇ to recover a 659 bp DNA piece carrying the RSV LTR promoter and the first 40 nucleotides coding for the signal peptide of human myeloperoxidase.
- a 26 bp Bglll-EcoRI synthetic double-stranded oKgonucleotide was generated to reconstruct the remaining sequence of the hMPO signal peptide.
- the three fragments obtained above were ligated together to yield the plasmid pNTV3321 (Fig. 9B).
- the last step of the construction consisted of exdsing from pNTV3321 a 1649 bp Bspl286I/BamHI DNA piece corresponding to the module coding for SSM ⁇ HN and of introducing it, blunted-ended, into the blunted HindJU and Hpal sites of plasmid pTNDPC2 (see above).
- the final construct, pNTV3330, illustrated in Fig.9C thus consists of a polydstronic eukaryotic expression vector carrying the SSMPQ ⁇ HN sequence fused upstream to the neo gene and under the control of the Rous Sarcoma Virus Long Terminal Repeat promoter element.
- Recombinant transfer plasmids pNTV3324, pNIV3325, pNIV3327 and pNTV3326, were transfected into vaccinia-infected CV-1 cells and recombinant viruses were isolated after Bromo-Uridine selection and plaque purification on the basis of their blue colour in the presence of X-gal. They will be referred to as W3324, W3325, W3327 and W3326 respectively.
- the human H143 fibroblast TK" strain was used preferably to the RAT2 cells for plaque assays.
- the vaccinia virus used to infect cells was of the WR type (origin Borysiewicz, L.K.) for the W3324, and the VR-119 type (edge ATCC) for W3325, W3327, and W3326.
- the recombinant vaccinia virus, W3324 was used to infect CV-1 cells in culture at a multipli ⁇ ty of infection 1 (m.o.i.l). Infected cells (about 3.10 ⁇ per assay) and spent culture medium (about 2ml) were collected between 16 and 17 hours post infection. The presence of the Fs + a" protein was identified by ELISA, Western blotting and immunopre ⁇ pitation on cell extracts and spent culture medium.
- ELISA a mixture of six monoclonal antibodies anti F (PIV3) was used to coat microtiter plates (Mab 4.454 - 4.478 - 4.549 - 4.519 - 4.726 - 4.789; E.Norrby, Swiss) and rabbit anti PrV3 antiserum (E.Norrby, Swiss) as capture antibody. Spedfic complexes were detected using alkaline phosphatase-conjugated affinity purified swine immunoglobulins to rabbit (Prosan) and an appropriate chromogenic substrate, according to standard procedures.
- Concanavalin A concentrated spent culture medium were resolved by electrophoresis on 12% SDS-polyacrylamide gels. After transfer onto nitrocellulose filters, separated proteins were probed with the rabbit anit PrV3 antiserum (E.Norrby, Sweden). Complexes were detected using a swine anti-rabbit IgG conjugated to alkaline phosphatase (Prosan) and the appropriate chromogenic substrate, according to standard procedures.
- Immunopredpitation experiments were performed as follows. In short, the recombinant product was labelled in vivo by growing the recombinant vaccinia virus in the presence of 35s-methionine. Labelled samples, cells extracts and medium, were incubated successively with the six monoclonal antibodies mixture anti F (PIV3) and rabbit anti-mouse; specific complexes were then recovered by binding to sepharose bound protein A. These procedures are well known to spedalists in the art. Tmmunopredpitates were analyzed onto 12% SDS-polyacrylamide gels which were then autoradiographed after drying.
- PIV3 monoclonal antibodies mixture anti F
- rabbit anti-mouse specific complexes were then recovered by binding to sepharose bound protein A.
- the product was distributed between cell extracts and spent culture medium (Fig.10 A).
- Western blotting analysis showed that the recombinant Fs+a" protein in concentrated spent culture medium migrates as the 70 kDa precursor (FQ) and as its subunit of 56 kDa 0F ⁇ ). This result was confirmed on cell extracts by the immunopredpitaion experiments.
- the recombinant vaccinia virus, W3325 was used to infect CV-1 cells in culture. All subsequent steps pertaining to the assays were as described supra, with the exception that a mixture of thirteen monoclonal antibodies anti HN (E.Norrby, Sweden) was used as selective probe. (Rydbeck ei al., J.Gen.Virol. £7_:1531-1542, 1986).
- the recombinant vaccinia virus W3327 was used to infect CV-1 cells in culture. All subsequent steps were as described supra.
- the presence of the SSJMPO ⁇ HN protein was identified by ELISA. As seen in Fig.lOB, the majority of the product is selected into the spent culture medium although about one fifth of the total amount remains intracellularly.
- the recombinant vaccinia virus, W3326 was used to infect CV-1 cells. All subsequent steps were as described supra.
- the data of the ELISA assay show that the majority of the recombinant Fs+a"xHNa" protein is secreted into the spent culture medium.
- the plasmid pRIT13572 was transfected by caldum phosphate co-predpitation into CHO-K1 cells, using 20 ⁇ g DNA per 1,25 x 10 ⁇ cells.
- the CHO-K1 cells were grown in GMEM-S medium.
- the GS transfectants were selected by addition of 25 ⁇ M methionine sulfoximine (MSX) two days after transfection in GMEM-S medium lacking glutamine and containing 10% dialysed FCS. Fresh medium replacements were performed each 4-5 days and 10 to 14 days later, resistant colonies were picked and transferred into 96 wells plates. Each transformant was then transferred into 24 wells plates and subsequently to 80 cm ⁇ flasks.
- MSX methionine sulfoximine
- the GS transformants were assayed for the Fs+a" protein 3-4 days after confluency. The procedure follows that one described in Cockett,M.L, Bebbington, C.R. and Yarranton, G.T., Bio/Technology £:662-667, 1990). Cell culture supernatants and extracts were assayed using ELISA and Western blotting as described supra.
- Plasmid pNTV3328 was introduced by electroporation into CHO cells. Selection of recombinant cell lines was done using genetidn (G418) and amplification of cell fines was performed using methotrexate. All procedures used follow those described in Moguilevsky et al.. (Eur.J.Biochemistry, 121: 605-614, 1991).
- G418 ⁇ clones were obtained and assayed for the production of the full size HN protein using the systems described before. Clones shown to produce the recombinant protein were amplified with methotrexate at different concentrations and retested for production. ELISA assays performed on the amplified cell lines showed that the recombinant HN protein was produced and that it accumulated into the CHO cells.
- Plasmid pNTV3331 was introduced by electroporation into CHO cells. All subsequent steps were as described supra.
- Random amplification of G418 resistant clones produced cell lines accumulating the recombinant protein, as identified by ELISA.
- Plasmid pNTV330 was introduced by electroporation into CHO cells. All subsequent steps were as described supra.
- G418-"- clones were assayed by ELISA for the production of the SSfyj O HN protein; some of the clones were positive in the assay and were amplified with various concentrations of methotrexate. Amplified cell lines were shown to secrete the recombinant protein into the culture medium.
- the ELISA assay shows that the distribution of the SS ⁇ po ⁇ HN recombinant product between cell extract and supernatant of a representative amplified cell line ⁇ HN (clone 3B) is about 90% in the medium and 10% in the cells.
Abstract
The invention relates to recombinant PIV3 fusion proteins or immunogenic derivatives thereof comprising a portion of the F protein of PIV3 fused to a portion of the HN protein of PIV3, methods of constructing and expressing these, intermediates for use therein and recombinant proteins obtained from the intermediates. Recombinant proteins of the invention have potential utility in the prevention of PIV3 infection.
Description
CHIMERAS OF PARAINFLUENZA VIRUS TYPE 3 PROTEINS F AND HN. AS VACCINES
The present invention relates to recombinant PIV 3 proteins, more particularly to the F and HN proteins, fusion proteins derived therefrom, and their expression in eukaryotic cells. The invention further relates to methods of constructing and expressing the said fusion proteins, intermediates for use therein and recombinant proteins which may be obtained from the intermediates. Recombinant proteins of the invention have potential utility in the development of vaccines for the prevention of PIV 3 infection.
Parainfluenza viruses are important pathogens of the respiratory tract in infants and young children. Some infections are not restricted to the upper respiratory tract but also invade the lower part of the respiratory system, particularly in children under 5 years of age. For a review see Parainfluenza Viruses (chapter 35); Channock, R.M. and Mclntosh, K. (1990) Virology. Second Edition, edited by B.N. Fields and D.N. Knipe. Raven Press, Inc. N.Y.; pp 963-988.
Together all parainfluenza virus infections are second only to those caused by the respiratory syncytial virus. PrV3 infections, in particular, are not only associated with the croup syndrome (as in the case of PIVl and PIV2) but more often cause bronchitis, bronchiolitis and pneumonia. PrV3 is responsible for most of the fatal infections observed with paramyxoviruses. In particular, severely immuno-compromised children are at risk of developing fatal giant cell pneumonia when infected with PTV3. (Jarvis, W.R.; Middleton, P.J. and Gelfand, E.W. (1979). J. Pediatr. 24, 423-425)
Almost 67% of infants are infected with PTV3 in the first year of life; by age 2, 92% of children have been infected at least once by PTV3 and 37% have been infected more than once. The first infection is most likely to cause lower respiratory tract diseases. (Glezen, W.P.; Frank, A.L.; Taber, L.H. and Kasel, J.A. (1984). J. Infec. Pis. 150. 851-857)
No efficient vaccine against PrV3 is available; earlier attempts with inactivated Pr 3 virus failed to induce resistance to the disease. New strategies currently being pursued include the use of cold-adapted
mutants of PIV3, the use of a bovine PTV3 and the development of subunit vaccines. The present invention relates to this last approach.
The fusion protein F of PrV3 contains 539 amino acid residues; amino acids 1 to 18 correspond to the signal peptide and residues 494 to 516 to the membrane anchor domain. The molecule presents potential sites for glycosylation. The F protein is synthesized as a 70 kDa precursor (Ffj) which undergoes proteolytic maturation to yield the Fi (56kDa) and F2 (14 kDa) subunits linked via disulfide bridges. The protein F, when injected into animals, leads to the production of neutralizing antibodies. The F protein is involved in cell fusion during viral infection and carries an hemolysϊn activity. Used alone for immunization, the F protein generates an immune response which is insufficient to confer protection against a challenge with the virus. Complete protection is only acquired by concomitant immunization with the protein HN, another glycoprotein ofPrV3.
The protein HN carries hemaglutinin and neuraminidase activities. It is composed of 572 amino acids; its membrane anchor domain occurs in the N-terminal end of the molecule, between amino acid residues 32 and 53. Four potential sites for glycosylation have been identified. Injection of protein HN into animals generates an immune response and neutralizing antibodies. These antibodies however do not protect completely against a challenge with the virus. Full protection is obtained only by concomitant immunization with the F protein of PTV3.
Accordingly there still exists a need for antigens which will effectively protect against challenge with the PIV3 virus.
According to a first aspect of the present invention there is provided recombinant DNA encoding a fusion protein or an immunogenic derivative thereof comprising a portion of the F protein of PIV3 fused to a portion of the HN protein of PTV3.
The term immunogenic derivative as used herein encompasses any molecule which is a fusion protein which is immunologically reactive with antibodies raised to the fusion protein of the present invention or parts thereof or which elicits antibodies recognizing the fusion protein, the HN
protein, the F protein or PIV3 virus. In particular immunogenic derivatives which are slightly longer or shorter than the fusion protein of the present invention may be used. Such derivatives may , for example, be prepared by substitution, addition, or rearrangement of amino acids or by chemical modifications thereof including those for enabling coupling of the fusion protein to other carrier proteins such as tetanus toxoid or Hepatitis B surface antigen. All such substitutions and modifications are generally well known to those skilled in the art of peptide chemistry.
Immunogenic fragments of the fusion protein which may be useful in the preparation of vaccines may be prepared by expression of the appropriate gene fragments or by peptide synthesis, for example using the Merrifield synthesis (The Peptides, Vol 2., Academic Press, New York, p3).
The recombinant DNA of the invention may form part of a vector, for example a plasmid, especially an expression plasmid from which the fusion protein may be expressed. Such vectors also form part of the invention, as do host cells into which the vectors have been introduced.
The invention further provides a fusion (or "hybrid') protein or an immunogenic derivative thereof comprising a portion of the F protein of PF73 fused to a portion of the HN protein of PrV3. Preferably the fusion is between an amino acid in the C-terminal part of a portion of the F protein and an amino acid at the N-terminus of a portion of the HN protein.
Preferably both the F protein and the HN protein components of the fusion protein of the invention lack a membrane anchor domain.
In one specific embodiment there is provided a fusion protein comprising amino acid residues 1 to 484 of the F protein fused to residues 88 to 572 of the HN protein (herein designated Fs+a- x HNa").
In order to construct the DNA encoding a fusion protein according to the invention, cDNA containing the complete coding sequences of the F and HN proteins may be manipulated using standard techniques [see for example Maniatis T. et al Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Harbor N.Y. (1982)] as further described hereinbelow.
Tn the course of carrying out such techniques recombinant DNA encoding fragments of the F and HN proteins may be obtained which further forms part of the present invention.
In particular DNA segments encoding the truncated protein Fs+a' (F protein lacking the membrane anchor domain) and the truncated protein HNa" (HN protein lacking the 5' membrane anchor domain) are important intermediates.
A further construct which may be obtained is DNA encoding the HNa" protein fused to a signal sequence from another gene, for example human myeloperoxidase (MPO). A particular embodiment is
Δ HN corresponding to a hybrid containing the 22 amino acid signal peptide of MPO fused to the last 519 amino acid residues of the HN protein (aa 53 to 572).
Vectors comprising such DNA, hosts transformed thereby and the truncated or hybrid proteins themselves, expressed as described hereinbelow all form part of the invention.
For expression of the proteins of the invention, plasmids may be constructed which are suitable either for transfer into vaccinia virus or transfection into Chinese Hamster Ovary (CHO) cells or Vero cells. Suitable expression vectors are described hereinbelow.
For expression in vaccinia a vaccinia transfer plasmid such as pTJLB 5213 which is a derivative of pSCll (Chakrabati ≤£ a . Molecular and Cellular Biology 5_, 3403 - 3409, 1985) may be used. In one aspect the protein may be expressed under the control of the vaccinia P7.5 promoter.
For expression in CHO cells a glutamine synthetase (GS) vector such as pEE14 may suitably be used so that the protein is expressed under the control of the major immediate early promoter of human cytomegalovirus (hCMV-MIE). Alternatively a vector which allows the expression of the coding module as a polycistronic transcript with the neo selection gene may suitably be used. In one preferred aspect the coding module is under the control of the Rous Sarcoma Long Terminal Repeat (LTR) promoter.
Preferably the plasmid for expression in CHO cells carries a DHFR expression cassette suitable for gene amplification using methotrexate.
Expression of full length HN in eukaryotic cells particularly CHO cells, is novel and forms a further aspect of the invention.
In order to define the invention more clearly reference is made to the appended drawings, in which:
Figure IA shows a schematic representation of the Fs+a" cDNA module which was used to construct a plasmid pNTV3305;
Figure IB shows a representation of plasmid pNIV3324 obtained by introducing the Fs+a" module into pULB 5213;
Figure 2A shows a representation of plasmid pNIV3308 carrying the sequence of HNa";
Figure 2B is a representation of plasmid pNTV3325 obtained by introducing the HNa" module into pULB5213;
Figure 3 is a representation of plasmid pNTV3327 obtained by introducing the SSMPO module into pULB5213;
Figure 4A is a representation of plasmid pNTV3310 obtained by introducing the FxHN DNA sequence into pUC9;
Figure 4B is a representation of plasmid pN3V3326 obtained by introducing the FxHN DNA sequence into pULB5212;
Figure 5 is a representation of the Fs+a" coding module as subcloned in a pTDN vector to give plasmid pNIV3306 together with a representation of pRIT13572 containing the Fs+a" coding module subcloned into pEE14;
Figure 6 is a representation of the Fs+a" x HNa" coding module recovered from pNrV3310 together with pRIT13571 containing the Fs+a" x HNa" sequence subcloned into pEE14;
Figure 7 is a representation of the complete HN protein coding sequence from plasmid pIBI-HN together with pNTV3328 containing the HN coding sequence subcloned into pTNDPC2;
Figure 8 is a representation of the HNa' coding module recovered from pNTV3308 together with pNTV3331 containing the HNa" coding sequence subcloned into pTNDPC2;
Figure 9A is a representation of the pNTV3319 containing the HNa" coding sequence subcloned into a pTDN vector;
Figure 9B shows the construction of plasmid pNTV3321 containing the SSMPO Δ HN coding sequence from pNTV3319 and pNTV2706; and
Figure 9C shows the SS^PO Δ ELN sequence from pNTV3321 introduced into pTNDPC2 to form pNTV3330.
In yet another aspect of the invention there is provided a vaccine composition comprising a protein according to the invention in combination with a pharmaceutically acceptable carrier, a protein according to the invention for use in vaccinating a host and the use of a protein according to the invention in the preparation of a vaccine.
Optionally , and advantageously, the Pr 3 vaccine of the present invention is combined with other immunogens to afford a polyvalent vaccine.
In a particular aspect the invention further provides a vaccine composition comprising a protein according to the invention and an antigen against respiratory syncytial virus (RSV) together with a suitable carrier or adjuvant. Antigens which stimulate production of antibodies against RSV in humans and animals are known in the art and examples are the major glycoprotein (G), fusion protein (F), phosphoprotein (P), nucleoprotein (N), and matrix (22K) protein of RSV A2 strain (a general review is given by Stott, E.J. and Taylor, G. (1985) in Archives of Virology,84, 1-52).
Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller ei l, University Park Press,
Baltimore, Maryland, U.S.A., 1978. Encapsulation within liposomes is described, for example by Fullerton, U.S. Patent 4,235,877.
In the vaccine of the present invention , an aqueous solution of the protein(s) can be used directly. Alternatively, the protein, with or without prior lyophilisation, can be mixed, absorbed or adsorbed with any of the various known adjuvants. Such adjuvants include, but are not limited to , alumimum hydroxide, muramyl dipeptide and saponins such as Quil A. Particularly preferred adjuvants are MPL (monophosphoryl lipid A) and 3D-MPL (3 deacylated monophosphoryl lipid A) [US patent 4,912,094]. A further preferred adjuvant is known as QS21 which can be obtained by the method disclosed in US patent 5,057,540. Use of 3D-MPL is described by Ribi ≤£ s in Microbiology (1986) Levie ≤£ aL(eds) Amer. Soc. Microbiol.Wash. D.C., 9-13. Use of Quil A is disclosed by Dalsgaard ≤£ al,(1977), Acia Ve cand. IS, 349.
As a further exemplary alternative, the proteins can be encapsulated within microparticles such as liposomes or associated with oil-in-water emulsions. Encapsulation within liposomes is described by Fullerton in US patent 4,235,877. In yet another exemplary alternative, the proteins can be conjugated to an immunostimulating macromolecule, such as killed Bordetella or a tetanus toxoid. Conjugation of proteins to macromolecules is disclosed, for example by Likhite in patent 4,372,945 and Armor el a in US patent 4,474,757.
The amount of the protein of the present invention present in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally, it is expected that each dose will comprise 1-1000 μg of protein, preferably 1-200 μg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects.
The invention will now be illustrated by reference to the following examples.
Example 1 Vector construction
A) For transfer into vaccinia virus
1. Fusion protein Fs+a~ t lacking the membrane anchor region
Starting from plasmid pIBIcod, a cDNA clone encoding the complete F protein (received from Dr. K. Eimock, University of Ottawa, Canada), we reconstructed a cDNA module coding for the F protein lacking the C-terminal membrane anchor sequence (Fs+a").
Plasmid pIBIcod was digested by Nsil and BamHI to recover a 4016 bp DNA fragment corresponding to the vector and amino acid residues 1 to 377 of the F protein. On the other hand, a 362 bp Nsil-BamHI DNA piece was generated by the polymerase chain reaction using plasmid pIBIcod as template; it corresponds to amino acid residues 378 to 493 of the F protein and includes a stop codon.
This fragment was ligated to the 4016 bp DNA piece obtained before to reconstruct a plasmid, pNTV3305, carrying the F protein lacking the anchor domain (Fig. IA).
The Fs+a" module (1492 bp) was then recovered from pNTV3305 by digestion with Hindm-BamHI and introduced blunt-ended, in the correct orientation for expression, into the Smal site of the vaccinia transfer plasmid pULB5213, which is a derivative of the standard vaccinia vector pSCll (Chakrabati e al. Molecular and Cellular Biology £, 3403-3409, 1985). The resulting plasmid, pNTV3324, is illustrated in Fig. IB.
2. Attachment protein HNa. lacking the 5' membrane anchor domain
Starting from plasmid pIBI-HN, a cDNA clone containing the complete coding sequence of protein HN as well as its 3' non coding sequence (received from Dr.K. Kimock, University of Ottawa, Canada), we reconstructed two different cDNA modules coding for the HN protein lacking the 5' membrane anchor domain. The first one, HNa consists of a strict deletion of amino acid residues 32 to 51 and the second one, SSMPQ HN, consists of a fusion between a synthetic signal sequence derived from
the human myeloperoxidase cDNA (Moguilevsky et al. Eur. J. Bicohemistry, 19J7_: 605-614, 1991) and amino acid residues 54 to 572 of the HN protein.
a) The module coding for HNa" was constructed as follows: plasmid pIBI-HN was digested with Asn718 and EcoRI to recover a 3935 bp DNA fragment corresponding to the vector and to amino acid residues 236 to 572 of the HN protein. In addition, two DNA fragments were generated by the polymerase chain reaction procedure using plasmid pIBI-HN as template; the first one is 117 bp EcoRI-HindlH piece spanning the initiation ATG (Metl), the sequence coding for amino acids 2 to 31 and the codon for amino acid residue 52 of the HN protein. The second fragment is a 556 bp HindHI-Asp718 DNA piece encoding amino acid residues 53 to 235 of the HN protein.
The three fragments obtained above were ligated to reconstruct a plasmid, pNTV3308 (Fig.2A) which carries the sequence of the HN protein lacking exclusively the anchor domain (sequence for amino acids 32 to 51). The HNa module (1688 bp) was then recovered from pNTV3308 by digestion with Xbal and introduced blunt-ended into the Smal site of the vaccinia transfer vector pULB5213 (see supra). The resulting plasmid, pNIV3325, is illustrated in Fig.2B.
b) The module coding for SSMPO A HN was constructed as follows: starting from plasmid pNTV3325 Fig 9B), which carries an hybrid sequence corresponding to the signal peptide (22 amino acids) of human myeloperoxidase fused to the last 519 amino acid residues of the HN protein (aa53 to 572), we excised a 1649 bp Bspl286I-BamHI DNA fragment which, after blunting, was ligated into the Smal site of the vaccinia transfer plasmid pULB5213.
The resulting plasmid, pNIV3327, is illustrated in Fig. 3.
3. An hybrid Fs+a"xHNa" protein
In this construction, the DNA coding for the HNa" protein is fused downstream to the DNA encoding the Fs+a" protein.
Plasmid pIBIcod (see supra) was digested with BamHI and Bj£LTI to recover a 4284 bp fragment corresponding to the vector and to amino add residues 1 to 466 of the F protein. On the other hand, plasmid pT-BI-HN (see supra) was digested with BamHI and Asel to recover a 1467 bp DNA piece corresponding to amino add residues 88 to 572 of the HN protein. At last, synthetic oligonucleotides (56/54 mers) were produced in order to provide the junction between the two fragments obtained above. These oligonucleotides are flanked by a BglTJ site on the 5' end and an Asel site on the 3' end, and code for amino add residues 467 to 484 of the F protein.
The three DNA fragments were ligated to generate the plasmid pNTV3309. To fadlitate further manipulation of the FxHN coding module, it was introduced into another vector, pUC9 (Pharmada) to yield pNTV3310 (Fig.4A). The hybrid FxHN DNA sequence (2949bp) was recovered from pNLV3310 by digested with BamHI and introduced by ligation into the BgHI site of the vacdnia transfer plasmid pULB5212 (pULB5212 is identical to pULB5213 except for the orientation of the multisite linker sequence; see supra) to generate the final plasmid pNTV3326 (Fig.4B). This plasmid thus contains, under the control of the vacdnia P7 5 promoter, an hybrid DNA sequence coding for 969 amino adds (residues 1 to 484 of the F protein fused to residues 88 to 572 of the HN protein.
B) For transfection into CHO cells
1. Fusion protein Fs+a" lacking the membrane anchor domain
The module coding for Fs+a", recovered from pNTV3305, was subcloned into the pTDN vector (Connors et al. DNA 2:651-660, 1988) in order to provide appropriate flanking restriction sites for future constructions. The resulting intermediate plasmid, pNTV3306, was then digested with Hmdiπ and SnaBI to recover the 1492 bp coding module. The DNA piece was ligated into the HindHI and Smal sites of the glutamine synthetase (GS) vector, pEE14 (Cockett ≤tal, Bio/Technology 8_:662-667, 1990). The resulting final plasmid, pRIT13572, contains the Fs+a~ protein under the control of the major immediate early promoter of the human cytomegalovirus (hCMV-MIE). The recombinant plasmid is illustrated in Figure 5.
2. The hybrid protein Fs+a"xHNa
The starting material pNTV3310, was digested with BamHI to recover the module encoding the Fs+a"xNHa hybrid protein. This fragment was inserted, blunt-ended and in the correct orientation for expression, by ligation into the Smal site of the pEE14 vector (see supra). The resulting plasmid, pRIT13571, contains under the control of the hCMC promoter, the sequence coding for the fusion between Fs+a" (aa residues 1 to 484) and HNa" (aa residues 88 to 572); it is illustrated in Fig. 6.
3. The attachment protein HN
Three constructions for expression in CHO cells have been made. The first one, HN, corresponds to the full coding sequence of the attachment protein, including the 5' membrane anchor domain. The second construction is the HNa" derivative, i.e. the attachment protein lacking exdusively the anchor sequence (amino add residues 31 to 52) and the third construction,
Δ HN, is a fusion between the signal sequence of human myeloperoxidase and a truncated form of the attachment protein.
a) The full coding sequence for the attachment protein HN
The starting material, pIBI-HN (see supra), was digested with BamHI to recover a 1736 bp DNA piece encoding the complete HN protein. The fragment was ligated, blunt-ended, to the blunted HindHI and Hpal sites of the eukaryotic expression vector pTNDPC2 (M.Reff, SmithKline Beecham, Philadelphia, USA). This vector is a derivative of pTDN (Connors et al. 1988, see supra) which allows the expression of a foreign DNA as a polydstronic transcript with the neo selection gene. The resulting plasmid, pNIV3328, thus carried the HN coding module upstream to the neo gene under the control of the Rous Sarcoma Long Terminal Repeat (LTR) promoter. In addition, the plasmid carried a DHFR expression cassette suitable for amplication using methotrexate. The plasmid is illustrated in Figure 7.
b) The HNa" protein, lacking the membrane anchor domain
(reaiduβs 31 to 52)
The starting material, pNLV3308 (see supra), was digested with Xbal to recover a 1684 bp fragment encoding the HNa" protein. The DNA piece was ligated, blunt-ended, to the blunted HindJU and Hpal sites of the eukaryotic polydstronic expression vector pTNDPC2 (see supra). The resulting plasmid, pNTV3331, carries the HNa" coding module upstream to the neo gene under the control of the RSVLTR promoter (Figure 8).
c) The SS Q Δ HN protein
The final plasmid for expression of SSMPQ. Δ HN in CHO cells was obtained in three steps. The first one consists in introducing the Xbal-Xbal 1684 bp coding cassette derived from pNTV3308 (see above, b) into the pTDN vector (Connors et al. 1988, see supra) to obtain the intermediate vector pNTV3310 (Fig.9A). From there, the actual construction of SSMPQ A HN was started. pNTV3319 was digested in Sail and EcoRI to recover a 7278 bp fragment corresponding to the nearly complete vector and to the HN amino adds 53 to 572. On the other hand, plasmid pNTV2706 (Moguilevsky et al. Eur.J. Biochemistry jL9_Z:605-614, 1991) which encodes human myeloperoxidase, was digested with Sail and Bgiπ to recover a 659 bp DNA piece carrying the RSV LTR promoter and the first 40 nucleotides coding for the signal peptide of human myeloperoxidase. At last, a 26 bp Bglll-EcoRI synthetic double-stranded oKgonucleotide was generated to reconstruct the remaining sequence of the hMPO signal peptide. The three fragments obtained above were ligated together to yield the plasmid pNTV3321 (Fig. 9B).
The last step of the construction consisted of exdsing from pNTV3321 a 1649 bp Bspl286I/BamHI DNA piece corresponding to the module coding for SSM Δ HN and of introducing it, blunted-ended, into the blunted HindJU and Hpal sites of plasmid pTNDPC2 (see above). The final construct, pNTV3330, illustrated in Fig.9C, thus consists of a polydstronic eukaryotic expression vector carrying the SSMPQ Δ HN sequence fused upstream to the neo gene and under the control of the Rous Sarcoma Virus Long Terminal Repeat promoter element.
Example 2
Expression in enkarvotic cells
A) via vacdnia virus recombinants
Recombinant transfer plasmids, pNTV3324, pNIV3325, pNIV3327 and pNTV3326, were transfected into vaccinia-infected CV-1 cells and recombinant viruses were isolated after Bromo-Uridine selection and plaque purification on the basis of their blue colour in the presence of X-gal. They will be referred to as W3324, W3325, W3327 and W3326 respectively. The human H143 fibroblast TK" strain was used preferably to the RAT2 cells for plaque assays. The vaccinia virus used to infect cells was of the WR type (origin Borysiewicz, L.K.) for the W3324, and the VR-119 type (origine ATCC) for W3325, W3327, and W3326.
The procedure follows that one previously described for the obtention of vacdnia virus recombinants (Mackett,M. and Smith, G.L., J. Gen.Virology £1:2067-2082, 1986; Mackett, M., Smith, G.L. and Moss, B., J. Virology 49_: 857-864, 1984).
1- Fusion protein Fs+a". lacking the membrane anchor domain
The recombinant vaccinia virus, W3324, was used to infect CV-1 cells in culture at a multipliάty of infection 1 (m.o.i.l). Infected cells (about 3.10^ per assay) and spent culture medium (about 2ml) were collected between 16 and 17 hours post infection. The presence of the Fs+a" protein was identified by ELISA, Western blotting and immunopreάpitation on cell extracts and spent culture medium. For ELISA, a mixture of six monoclonal antibodies anti F (PIV3) was used to coat microtiter plates (Mab 4.454 - 4.478 - 4.549 - 4.519 - 4.726 - 4.789; E.Norrby, Stockholm) and rabbit anti PrV3 antiserum (E.Norrby, Stockholm) as capture antibody. Spedfic complexes were detected using alkaline phosphatase-conjugated affinity purified swine immunoglobulins to rabbit (Prosan) and an appropriate chromogenic substrate, according to standard procedures.
For Western blotting experiments, Concanavalin A concentrated spent culture medium were resolved by electrophoresis on 12%
SDS-polyacrylamide gels. After transfer onto nitrocellulose filters, separated proteins were probed with the rabbit anit PrV3 antiserum (E.Norrby, Stockholm). Complexes were detected using a swine anti-rabbit IgG conjugated to alkaline phosphatase (Prosan) and the appropriate chromogenic substrate, according to standard procedures.
Immunopredpitation experiments were performed as follows. In short, the recombinant product was labelled in vivo by growing the recombinant vaccinia virus in the presence of 35s-methionine. Labelled samples, cells extracts and medium, were incubated successively with the six monoclonal antibodies mixture anti F (PIV3) and rabbit anti-mouse; specific complexes were then recovered by binding to sepharose bound protein A. These procedures are well known to spedalists in the art. Tmmunopredpitates were analyzed onto 12% SDS-polyacrylamide gels which were then autoradiographed after drying.
The ELISA indicated that the recombinant Fs+a" protein is expressed in CV-1 cells infected with W3324. The product was distributed between cell extracts and spent culture medium (Fig.10 A). Western blotting analysis showed that the recombinant Fs+a" protein in concentrated spent culture medium migrates as the 70 kDa precursor (FQ) and as its subunit of 56 kDa 0Fχ). This result was confirmed on cell extracts by the immunopredpitaion experiments.
2. The attachment protein HNa". lacking the 5' membrane anchor domain
The recombinant vaccinia virus, W3325, was used to infect CV-1 cells in culture. All subsequent steps pertaining to the assays were as described supra, with the exception that a mixture of thirteen monoclonal antibodies anti HN (E.Norrby, Stockholm) was used as selective probe. (Rydbeck ei al., J.Gen.Virol. £7_:1531-1542, 1986).
3. The attachment protein SSMPQ A HN
The recombinant vaccinia virus W3327 was used to infect CV-1 cells in culture. All subsequent steps were as described supra. The presence of the SSJMPO Δ HN protein was identified by ELISA. As seen in Fig.lOB,
the majority of the product is selected into the spent culture medium although about one fifth of the total amount remains intracellularly.
4. The hybrid Fs+a-xHNa" protein
The recombinant vaccinia virus, W3326, was used to infect CV-1 cells. All subsequent steps were as described supra. The data of the ELISA assay show that the majority of the recombinant Fs+a"xHNa" protein is secreted into the spent culture medium.
B) Expression in CHO cells (stable transformants)
1. The fusion protein Fs+a". lacking the membrane anchor domain
The plasmid pRIT13572 was transfected by caldum phosphate co-predpitation into CHO-K1 cells, using 20 μg DNA per 1,25 x 10^ cells. The CHO-K1 cells were grown in GMEM-S medium. The GS transfectants were selected by addition of 25μM methionine sulfoximine (MSX) two days after transfection in GMEM-S medium lacking glutamine and containing 10% dialysed FCS. Fresh medium replacements were performed each 4-5 days and 10 to 14 days later, resistant colonies were picked and transferred into 96 wells plates. Each transformant was then transferred into 24 wells plates and subsequently to 80 cm^ flasks. The GS transformants were assayed for the Fs+a" protein 3-4 days after confluency. The procedure follows that one described in Cockett,M.L, Bebbington, C.R. and Yarranton, G.T., Bio/Technology £:662-667, 1990). Cell culture supernatants and extracts were assayed using ELISA and Western blotting as described supra.
Gene amplication procedures were done as described previously (Cockett et al.. see supra). The distribution of the Fs+a" protein between cell extract and supernatant of clones obtained during the first screening was measured. The data of the ELISA show that about 80%-90% of the product is secreted into the medium.
2. The hybrid protein Fs+a~xHNa~
Procedures for expression of the hybrid Fs+a~xHNa" protein in CHO cells
transfected with plasmid pRIT13571 followed those described above. Cell culture supernatants and extracts were assayed using ELISA and Western blotting. Gene amplification procedures were done as described previously (Cockett et al.. see supra).
The distribution of the hybrid Fs+a"xHNa" protein between cell extract and supernatant of a representative cell line Fs+a"xHNa" clone 6 obtained by an ELISA assay was measured. The product was almost evenly distributed between cells and medium.
3. The attachment protein HN (complete protein)
Plasmid pNTV3328 was introduced by electroporation into CHO cells. Selection of recombinant cell lines was done using genetidn (G418) and amplification of cell fines was performed using methotrexate. All procedures used follow those described in Moguilevsky et al.. (Eur.J.Biochemistry, 121: 605-614, 1991).
G418^ clones were obtained and assayed for the production of the full size HN protein using the systems described before. Clones shown to produce the recombinant protein were amplified with methotrexate at different concentrations and retested for production. ELISA assays performed on the amplified cell lines showed that the recombinant HN protein was produced and that it accumulated into the CHO cells.
4. The attachment protein HNa", lacking the membrane anchor domain
Plasmid pNTV3331 was introduced by electroporation into CHO cells. All subsequent steps were as described supra.
Random amplification of G418 resistant clones produced cell lines accumulating the recombinant protein, as identified by ELISA.
5. The attachment protein SSjyrpQ Δ HN
Plasmid pNTV330 was introduced by electroporation into CHO cells. All subsequent steps were as described supra. G418-"- clones were assayed by
ELISA for the production of the SSfyj O HN protein; some of the clones were positive in the assay and were amplified with various concentrations of methotrexate. Amplified cell lines were shown to secrete the recombinant protein into the culture medium. The ELISA assay shows that the distribution of the SS^po Δ HN recombinant product between cell extract and supernatant of a representative amplified cell line
Δ HN (clone 3B) is about 90% in the medium and 10% in the cells.
Claims
1. A fusion protein or an immunogenic derivative thereof comprising a portion of the F protein of PIV3 fused to a portion of the HN protein of PIV3.
2. A fusion protein or an immunogenic derivative thereof as daimed in claim 1 , wherein the fusion is between an amino add in the C-terminal part of a portion of the F protein and an amino add at the N-terminus of a portion of the HN protein.
3. A fusion protein or an immunogenic derivative thereof as claimed in claim 1 or 2, wherein both the F protein and the HN protein components of the fusion protein of the invention lack a membrane anchor domain.
4. A fusion protein or an immunogenic derivative thereof as daimed in any preceding claim comprising amino add residues 1 to 484 of the F protein fused to residues 88 to 572 of the HN protein.
5. Recombinant DNA encoding a fusion protein or an immunogenic derivative thereof as defined in any one of claims 1 to 4.
6. Recombinant DNA encoding a truncated protein or an immunogenic deriviative thereof comprising the F protein lacking the anchor protein domain or the HN protein lacking the 5' membrane anchor domain.
7. Recombinant DNA encoding the HNa" protein or an immunogenic derivative thereof fused to a signal sequence from another gene.
8. Recombinant DNA as claimed in claim 7 wherein the signal sequence comprises a hybrid protein sequence containing the 22 amino add signal peptide of MPO fused to the amino add residues 53 to 572 of the HN protein.
9. An expression vector comprising recombinant DNA as defined in any one of claims 5 to 8.
10. A host transformed with a vector as defined in claim 9.
11. A vacdne composition comprising a protein as defined in any one of claims 1 to 4 or an immunogenic derivative thereof in admixture with a pharmaceutically acceptable carrier.
12. A vacdne composition as claimed in claim 11 which further comprises an antigen effective in stimulating production of antibodies to respiratory syncytial virus.
13. A vacdne composition as claimed in claim 11 or claim 12 further comprising 3D Monophosphoryl lipid A or QS-21.
14. A vacdne composition as claimed in any one of claims 11 to 13 wherein the carrier is an oil-in-water emulsion.
15. A fusion protein or an ύnmunogenic derivative thereof as defined in any one of claims 1 to 4 for use in medicine.
16. A vaccine composition as defined in any one of claims 11 to 14 for use in medidne.
17. A process for the production of a fusion protein as defined in any one of claims 1 to 4 which process comprises expressing a DNA sequence encoding said protein in a host cell and recovering the protein.
18. A method of treating a human or animal susceptible to PrV3 infections comprising administering an effective amount of a vacdne as defined in any one of claims 11 to 14.
19. A process for the production of full length HN comprising expressing a DNA sequence encoding full length HN in a eukaryotic cell and recovering the protein.
20. A process as claimed in claim 19 wherein the eukaryotic cell is a CHO cell.
21. Use of a protein or an immunogenic derivative thereof as defined in any one of claims 1 to 4 in the manufacture of a medicament for use in the treatment of viral infections.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9120221.8 | 1991-09-23 | ||
GB919120221A GB9120221D0 (en) | 1991-09-23 | 1991-09-23 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993006218A2 true WO1993006218A2 (en) | 1993-04-01 |
WO1993006218A3 WO1993006218A3 (en) | 1993-05-27 |
Family
ID=10701826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/002174 WO1993006218A2 (en) | 1991-09-23 | 1992-09-18 | Chimeras of parainfluenza virus type 3 proteins f and hn as vaccines |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU2566092A (en) |
GB (1) | GB9120221D0 (en) |
MX (1) | MX9205367A (en) |
PT (1) | PT100885A (en) |
WO (1) | WO1993006218A2 (en) |
ZA (1) | ZA927199B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0705109A1 (en) † | 1993-05-25 | 1996-04-10 | American Cyanamid Company | Adjuvants for vaccines against respiratory syncytial virus |
FR2726471A1 (en) * | 1994-11-07 | 1996-05-10 | Pf Medicament | METHOD FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGEN COMPOUND OR HAPTENE AND APPLICATION TO VACCINE PREPARATION |
US6165774A (en) * | 1995-09-22 | 2000-12-26 | Connaught Laboratories Limited | Parainfluenza virus glycoproteins and vaccines |
US6331425B1 (en) * | 1995-07-05 | 2001-12-18 | Endozyme Limited | Recombinant protein having bacteriophage endosialidase enzymatic activity |
US6333395B1 (en) * | 1993-06-07 | 2001-12-25 | Shawn Barney | Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission |
US6830748B1 (en) | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
CN104513317A (en) * | 2013-09-30 | 2015-04-15 | 普莱柯生物工程股份有限公司 | Vaccine composition, preparation method and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010405A1 (en) * | 1988-04-22 | 1989-11-02 | The Upjohn Company | Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3 |
-
1991
- 1991-09-23 GB GB919120221A patent/GB9120221D0/en active Pending
-
1992
- 1992-09-18 WO PCT/EP1992/002174 patent/WO1993006218A2/en active Application Filing
- 1992-09-18 AU AU25660/92A patent/AU2566092A/en not_active Abandoned
- 1992-09-21 ZA ZA927199A patent/ZA927199B/en unknown
- 1992-09-21 PT PT100885A patent/PT100885A/en not_active Application Discontinuation
- 1992-09-22 MX MX9205367A patent/MX9205367A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010405A1 (en) * | 1988-04-22 | 1989-11-02 | The Upjohn Company | Chimeric glycoproteins containig immunogenic segments of human parainfluenza virus type 3 |
Non-Patent Citations (3)
Title |
---|
ELECTRONIC DATABASE MEDLINE, U.S. NATIONAL LIBRARY OF MEDICINE (NLM) BETHESDA, US; AN88072000 E.J. SCOTT ET AL. 'Field trial of a quadrivalent vaccine against calf respiratory disease' * |
VIROLOGY vol. 160, 1987, NEW YORK, US pages 465 - 472 K.L. VAN WYKE COELINGH ET AL. 'Expression of Biologically Active and Antigenically Authentic Parainfleunza Type 3 Virus Hemagglutinin-Neuraminidase Glycoprotein by a Recombinant Baculovirus' * |
VIRUS RESEARCH vol. 12, 1989, AMSTERDAM, THE NETHERLANDS pages 169 - 180 R. RAY ET AL. 'Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property' * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0705109B2 (en) † | 1993-05-25 | 2004-01-02 | American Cyanamid Company | Adjuvants for vaccines against respiratory syncytial virus |
EP0705109A1 (en) † | 1993-05-25 | 1996-04-10 | American Cyanamid Company | Adjuvants for vaccines against respiratory syncytial virus |
US6333395B1 (en) * | 1993-06-07 | 2001-12-25 | Shawn Barney | Compositions for inhibition of membrane fusion-associated events, including human parainfluenza virus transmission |
US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
US6149911A (en) * | 1994-11-07 | 2000-11-21 | Pierre Fabre Medicament | Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines |
US6558673B1 (en) | 1994-11-07 | 2003-05-06 | Pierre Fabre Medicament | Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule |
WO1996014416A1 (en) * | 1994-11-07 | 1996-05-17 | Pierre Fabre Medicament | Method for enhancing the immunogenicity of an immunogenic compound or hapten, and use thereof for preparing vaccines |
FR2726471A1 (en) * | 1994-11-07 | 1996-05-10 | Pf Medicament | METHOD FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGEN COMPOUND OR HAPTENE AND APPLICATION TO VACCINE PREPARATION |
US6331425B1 (en) * | 1995-07-05 | 2001-12-18 | Endozyme Limited | Recombinant protein having bacteriophage endosialidase enzymatic activity |
US6165774A (en) * | 1995-09-22 | 2000-12-26 | Connaught Laboratories Limited | Parainfluenza virus glycoproteins and vaccines |
US6830748B1 (en) | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
US7205013B2 (en) | 1997-09-26 | 2007-04-17 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
US8889146B2 (en) | 2009-06-24 | 2014-11-18 | Glaxosmithkline Biologicals, Sa | Vaccine |
CN104513317A (en) * | 2013-09-30 | 2015-04-15 | 普莱柯生物工程股份有限公司 | Vaccine composition, preparation method and application thereof |
CN104513317B (en) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | A kind of vaccine composition and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
PT100885A (en) | 1993-11-30 |
WO1993006218A3 (en) | 1993-05-27 |
AU2566092A (en) | 1993-04-27 |
ZA927199B (en) | 1993-06-14 |
MX9205367A (en) | 1993-03-01 |
GB9120221D0 (en) | 1991-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3290662B2 (en) | Chimeric immunogen | |
KR960013578B1 (en) | Respiratory syncytial virus vaccine and diagnosis | |
US5880104A (en) | Nucleic acid respiratory syncytial virus vaccines | |
Taylor et al. | Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens | |
AU778144B2 (en) | Nucleic acid respiratory syncytial virus vaccines | |
Wathen et al. | Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector | |
CA2427578C (en) | A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine | |
NZ230425A (en) | Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector | |
JPH05262667A (en) | Vaccine using viral antigen | |
JPH11513372A (en) | Parainfluenza virus glycoproteins and vaccines | |
WO2000018929A2 (en) | Paramyxovirus vaccines | |
WO1993006218A2 (en) | Chimeras of parainfluenza virus type 3 proteins f and hn as vaccines | |
JPH08504090A (en) | Anti-feline immunodeficiency virus (FIV) vaccine | |
Ray et al. | Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property | |
JP2001512662A (en) | Nucleic acid vaccine encoding G protein of respiratory syncytial virus | |
WO2000043527A1 (en) | Varicella-zoster virus vaccines | |
EP0423869B1 (en) | Infectious bronchitis virus vaccine | |
EP0695358A1 (en) | Recombinant antigens from mumps virus and their use in vaccines | |
AU672870B2 (en) | Vaccines against varicella-zoster virus (VZV) | |
Corvaisier et al. | Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein | |
Snell et al. | Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells | |
WO1989004835A1 (en) | HUMAN RESPIRATORY SYNCYTIALVIRUS VACCINE DERIVED FROM THE 1A (9.5 kD) PROTEIN | |
JP2004520331A (en) | Chimeric T helper cell-B cell peptide vaccine against Japanese encephalitis virus | |
MXPA00000636A (en) | Nucleic acid vaccines encoding g protein of respiratory syncytial virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |